FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2988796616> ?p ?o ?g. }

• W2988796616 endingPage "2827" @default.
• W2988796616 startingPage "2827" @default.
• W2988796616 abstract "Introduction Indolent lymphomas, such as follicular lymphoma (FL) and marginal zone lymphoma (MZL), are highly radiosensitive and often respond to very low dose radiation therapy (VLDRT). We investigated the outcomes of patients treated with 4 Gy from a large, contemporary, real world cohort, and a subset of potentially curable (PC) patients with early stage (Ann Arbor stage I-II) disease and no prior therapy to the targeted lesion(s) before VLDRT. Methods We analyzed 256 treated sites from 210 consecutive adult patients (Table 1) with FL or MZL who were treated with VLDRT of 2 Gy x 2 fractions between 2006 and 2019 at our comprehensive cancer center. Initial overall response rate (ORR) was defined as complete response (CR) or partial response (PR) using Lugano criteria at first follow-up post-RT (median: 2.1 months; Interquartile range: 1.6-2.5 months). Stable disease (SD) or progressive disease (PD) at 2 months post-RT were considered local failure (LF). Freedom from local failure (FFLF) was defined as time from VLDRT to LF. Patients were censored at the start of a subsequent line of therapy if the VLDRT-treated site had not progressed. Event-free survival (EFS) was calculated per patient from VLDRT to LF or distant PD. FFLF and EFS were estimated using Kaplan-Meier and compared using log-rank. Results Initial ORR for all sites was 88% (CR: 65%, PR: 23%); 12% (n=31) were initially nonresponding (SD: 7%, PD: 5%). Thirteen sites with initial PR/SD/PD received additional RT (median: 30 Gy) within 6 months of VLDRT and had subsequent CR (n=7), PR (n=5), and PD (n=1). With median follow-up of 21 months, 2-year FFLF was 70%. Initial response to VLDRT was prognostic with a significantly improved 2-year FFLF for sites with CR (n=166) compared to those with PR (n=58) (88% vs. 66%, p<0.001). There was improved 2-year FFLF for extranodal versus nodal disease (81% vs. 58%, p=0.001) but not for previously untreated versus relapsed/refractory (76% vs. 68%, p=0.12) or early versus advanced stage sites (72% vs. 68%, p=0.98). In the subset of PC patients (n=50), there were 52 lesions. The histology of these sites was split between FL (n=21, 41%), MZL (n=22, 42%) and indolent lymphoma not further classified (n=9, 17%). The majority of the lesions in the PC cohort were extranodal (n=42, 81%). Median follow-up was 1 year with a 1-year EFS of 82%. Of the 12 PC patients who progressed post VLDRT, two thirds developed a distant site of recurrence outside of the VLDRT field. In field recurrence alone was rare (n=4). Diffuse large B cell lymphoma transformation after VLDRT was rare in the PC (n=0) and overall (n=6, 3%) cohort; all cases of transformed DLBCL were diagnosed out of VLDRT field. Conclusions Overall, patients with FL and MZL treated with only 4 Gy have excellent initial ORR. Upfront CR is prognostic of improved disease control. Early evaluation following VLDRT identifies nonresponders who may benefit from additional RT and spares many patients from higher doses of RT with durable local control. Our analysis of PC patients suggests that VLDRT does not compromise the standard curative RT approach. Disclosures No relevant conflicts of interest to declare." @default.
• W2988796616 created "2019-11-22" @default.
• W2988796616 creator A5000016659 @default.
• W2988796616 creator A5000509600 @default.
• W2988796616 creator A5001663845 @default.
• W2988796616 creator A5007588773 @default.
• W2988796616 creator A5023759382 @default.
• W2988796616 creator A5049426344 @default.
• W2988796616 creator A5072467991 @default.
• W2988796616 creator A5074971164 @default.
• W2988796616 date "2019-11-13" @default.
• W2988796616 modified "2023-09-30" @default.
• W2988796616 title "Outcomes of 210 Patients with Follicular and Marginal Zone Lymphomas Treated with 4 Gy of Radiation Therapy" @default.
• W2988796616 doi "https://doi.org/10.1182/blood-2019-132275" @default.
• W2988796616 hasPublicationYear "2019" @default.
• W2988796616 type Work @default.
• W2988796616 sameAs 2988796616 @default.
• W2988796616 citedByCount "3" @default.
• W2988796616 countsByYear W29887966162020 @default.
• W2988796616 countsByYear W29887966162021 @default.
• W2988796616 crossrefType "journal-article" @default.
• W2988796616 hasAuthorship W2988796616A5000016659 @default.
• W2988796616 hasAuthorship W2988796616A5000509600 @default.
• W2988796616 hasAuthorship W2988796616A5001663845 @default.
• W2988796616 hasAuthorship W2988796616A5007588773 @default.
• W2988796616 hasAuthorship W2988796616A5023759382 @default.
• W2988796616 hasAuthorship W2988796616A5049426344 @default.
• W2988796616 hasAuthorship W2988796616A5072467991 @default.
• W2988796616 hasAuthorship W2988796616A5074971164 @default.
• W2988796616 hasBestOaLocation W29887966161 @default.
• W2988796616 hasConcept C10515644 @default.
• W2988796616 hasConcept C119060515 @default.
• W2988796616 hasConcept C126322002 @default.
• W2988796616 hasConcept C126894567 @default.
• W2988796616 hasConcept C141071460 @default.
• W2988796616 hasConcept C146357865 @default.
• W2988796616 hasConcept C151730666 @default.
• W2988796616 hasConcept C2776694085 @default.
• W2988796616 hasConcept C2777058707 @default.
• W2988796616 hasConcept C2778822529 @default.
• W2988796616 hasConcept C2779338263 @default.
• W2988796616 hasConcept C2989005 @default.
• W2988796616 hasConcept C509974204 @default.
• W2988796616 hasConcept C66339696 @default.
• W2988796616 hasConcept C71924100 @default.
• W2988796616 hasConcept C72563966 @default.
• W2988796616 hasConcept C86803240 @default.
• W2988796616 hasConcept C90924648 @default.
• W2988796616 hasConceptScore W2988796616C10515644 @default.
• W2988796616 hasConceptScore W2988796616C119060515 @default.
• W2988796616 hasConceptScore W2988796616C126322002 @default.
• W2988796616 hasConceptScore W2988796616C126894567 @default.
• W2988796616 hasConceptScore W2988796616C141071460 @default.
• W2988796616 hasConceptScore W2988796616C146357865 @default.
• W2988796616 hasConceptScore W2988796616C151730666 @default.
• W2988796616 hasConceptScore W2988796616C2776694085 @default.
• W2988796616 hasConceptScore W2988796616C2777058707 @default.
• W2988796616 hasConceptScore W2988796616C2778822529 @default.
• W2988796616 hasConceptScore W2988796616C2779338263 @default.
• W2988796616 hasConceptScore W2988796616C2989005 @default.
• W2988796616 hasConceptScore W2988796616C509974204 @default.
• W2988796616 hasConceptScore W2988796616C66339696 @default.
• W2988796616 hasConceptScore W2988796616C71924100 @default.
• W2988796616 hasConceptScore W2988796616C72563966 @default.
• W2988796616 hasConceptScore W2988796616C86803240 @default.
• W2988796616 hasConceptScore W2988796616C90924648 @default.
• W2988796616 hasIssue "Supplement_1" @default.
• W2988796616 hasLocation W29887966161 @default.
• W2988796616 hasOpenAccess W2988796616 @default.
• W2988796616 hasPrimaryLocation W29887966161 @default.
• W2988796616 hasRelatedWork W1981639878 @default.
• W2988796616 hasRelatedWork W2061205584 @default.
• W2988796616 hasRelatedWork W2061253854 @default.
• W2988796616 hasRelatedWork W2353103559 @default.
• W2988796616 hasRelatedWork W2376163507 @default.
• W2988796616 hasRelatedWork W2612331381 @default.
• W2988796616 hasRelatedWork W4200055991 @default.
• W2988796616 hasRelatedWork W4311732874 @default.
• W2988796616 hasRelatedWork W4311742331 @default.
• W2988796616 hasRelatedWork W4312107372 @default.
• W2988796616 hasVolume "134" @default.
• W2988796616 isParatext "false" @default.
• W2988796616 isRetracted "false" @default.
• W2988796616 magId "2988796616" @default.
• W2988796616 workType "article" @default.